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Abstract
Background: HIV infection reduces the likelihood that individuals with pulmonary tuberculosis are smear positive
and that they have cavitatory disease. Antiretroviral therapy (ART) may shift the pattern of disease to be more
similar to that of HIV negative patients. This would aid diagnosis- which often depends on sputum smears – but
would also increase infectiousness. We assessed the effect of HIV and ART on smear positivity and cavitatory disease
in laboratory-confirmed pulmonary TB patients.
Methods: Three sputum samples were collected per pulmonary TB suspect and were examined using microscopy
and culture. Chest radiographs were available for a subset of patients as part of another study. The effect of HIV
and ART status on sputum smear positivity and lung cavitation were evaluated using multivariable logistic
regression.
Results: Of 1024 laboratory-confirmed pulmonary TB patients who were identified between January 2005 and
December 2011, 766 had HIV and ART status available. Positive sputum smears were significantly more common
among HIV negative individuals than HIV positive individuals (adjusted OR = 2.91, 95% CI 1.53 – 5.55). Compared to
those HIV positive but not on ART, patients on ART were more likely to be smear positive (adjusted OR = 2.33, 95%
CI 1.01 – 5.39) if they had been on ART ≤ 6 months, but only slightly more likely to be smear positive (adjusted
OR = 1.43, 95% CI 0.68 – 2.99) if they were on ART > 6 months. HIV negative patients were more likely than HIV positive
patients to have cavitatory disease (adjusted OR = 1.97, 95% CI 1.20 – 3.23). Patients on ART > 6 months had a slight
increase in cavitatory disease compared to HIV positive patients not on ART (adjusted OR = 1.68, CI 0.78 – 3.63).
Conclusions: HIV infection is associated with less smear positivity and cavitation in pulmonary TB patients. Among HIV
positive patients, the use of ART shifts the presentation of disease towards that seen in HIV-negative individuals, which
facilitates diagnosis but which also could increase infectiousness.
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Background
Tuberculosis (TB) is a major public health challenge.
Globally there were an estimated 8.7 million incident
cases of TB in 2011, 26% of which occurred in Africa,
and 1.4 million TB deaths [1]. 13% (1.1 million) of the
incident cases were HIV positive. In Malawi the number
of TB cases notified to the National TB Control
Programme rose sharply from 12,395 (132 per 100,000
population) in 1990 to 25,491 (199 per 100,000 popula-
tion) in 2005 [2]. The upsurge in TB was largely due to
HIV infection. HIV increases the risk of rapid TB progres-
sion after primary infection or re-infection with Mycobac-
terium tuberculosis (Mtb) and increases the risk of
reactivating latent TB infection [3,4]. In HIV negative in-
dividuals infected with Mtb, the lifetime risk of developing
TB disease is between 10% and 20% while in those co-
infected with HIV the annual risk is 10% or more [5,6].
The Malawi government, with assistance from the
Global Fund on Tuberculosis, Malaria and HIV/AIDS,
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started provision of antiretroviral therapy (ART) to HIV-
infected eligible individuals in 2004. By mid-2006 there
were 94 facilities providing ART and the total number of
patients alive and on ART was 41,549 [7]. The provision
of ART has been widely scaled up including the introduc-
tion of “Option B+” in Malawi in July 2011 with which all
HIV-infected pregnant and breastfeeding women are
started on lifelong ART regardless of clinical or immuno-
logical stage. By the end of 2012 there were 651 static
ART sites and 585 sites providing Option B+ and a total of
404,905 HIV-infected individuals on ART [8]. Since the
introduction and rolling out of ART in Malawi TB notifi-
cation rates have started to decline, with 25,491 (199 per
100,000 population) in 2005, 23,929 (171 per 100,000
population) in 2008, 22, 674 (157 per 100,000 population)
in 2009 and 21,092 (142 per 100,000 population) in 2010
[2]. In HIV-infected individuals, ART reduces the inci-
dence of TB, although rates remain higher than in HIV
negative patients [9-11].
Sputum smear microscopy has been the backbone for
the diagnosis of pulmonary TB in most low-income
countries because of its low cost, and is directly related
to infectiousness [12-14]. Due to paucibacillary pulmon-
ary disease in patients infected with HIV, the use of
smear microscopy in the diagnosis of pulmonary TB is
not ideal, although widely used [14]. In HIV-infected,
immunocompromised individuals, lung cavitation is less
frequent because the defective specific cell-mediated im-
mune response reduces the ability to mount a granu-
lomatous response to Mtb [15,16].
ART is widely used and has significantly improved the
prognosis of HIV-infected patients. The objective of this
study is to assess the effect of HIV and ART on the pres-
ence of smear positivity and cavitation at diagnosis of
laboratory-confirmed pulmonary TB, and to understand if
ART may affect infectiousness of HIV positive TB patients.
Methods
Study setting
Karonga district is situated in northern Malawi and has a
population of approximately 300,000 [17]. The district has
a district hospital and several health centres. The Karonga
Prevention Study has been conducting research on tuber-
culosis in the district since 1988. Pulmonary TB cases
were identified through enhanced passive surveillance: in-
dividuals with a cough of at least two weeks visiting health
facilities within the district were investigated for pulmon-
ary TB. Individuals were also identified by community
screening in the context of other related research studies,
but this practice yielded few cases. Individuals suspected
of having pulmonary TB were asked to submit three spu-
tum specimens, one collected on-the- spot, a second early
morning specimen and a third specimen collected on-the-
spot at the time of delivery of the second specimen, as per
Malawi National TB Programme guidelines [18,19].
Laboratory methods
Sputum smear examination was performed at the re-
search project laboratory using fluorescence micros-
copy with auramine staining, with confirmation of
positive smears by light microscopy using Ziehl-Neelsen
(ZN) stain. All sputum specimens were then cultured
using Lowenstein- Jensen solid media [20]. Cultures sug-
gestive of TB were sent to the National Mycobacterium
Reference Laboratory (Health Protection Agency) in the
UK for species confirmation and drug sensitivity testing.
Case definition
A pulmonary TB case was defined as being laboratory
confirmed if at least one sputum smear or culture was
positive. Those with no positive culture and only a single
scanty smear (<10 acid-fast bacilli per 100 High Powered
Fields) were excluded.
Study population, data collection and statistical methods
All confirmed pulmonary TB cases in Karonga District
aged ≥15 years and diagnosed between January 2005 and
December 2011 were included in the study. After written
informed consent, study participants were interviewed
using a standard structured questionnaire. In individuals
aged <18 years a written informed consent was obtained
from their parents or guardians at the time of the inter-
view. Patients were asked about sociodemographic char-
acteristics and history of previous TB.
Chest radiographs were available for a group of pa-
tients, most of whom were enrolled in immunological
studies. The objective of these studies was to develop a
rapid, sensitive, and affordable biological marker (gen-
omic or proteomic) for diagnosis of TB. Inclusion cri-
teria for immunological studies included: willingness to
undergo an HIV test and give a venous blood sample,
and aged 18 years or over. Exclusion criteria were a past
history of cancer, taking steroids in the past 6 months,
pregnancy and diabetes: few individuals were excluded
for these reasons. Radiographs were independently
reviewed by a chest physician or a radiologist following a
standardised format that assessed the presence of cavita-
tion, parenchymal consolidation, pleural effusion, miliary
pattern infiltrates and other radiological abnormalities.
These readers were blinded to the HIV and ART status
of the patients. They were also blinded to the diagnosis
of the patient, which was possible because they were also
reviewing chest radiographs for individuals with illnesses
other than TB.
Pulmonary TB patients were pre and post-test coun-
selled for HIV by trained counsellors. After interview
and if written consent was given blood was taken. In
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2005 – 2007, HIV testing was done using ELISA (Vironostika;
Organon Teknika, Cambridge, UK) and particle agglu-
tination test (Edgeware modification of the Serodia).
Positives were confirmed using a further ELISA (Wellco-
zyme Wellcome Diagnostics, Dartford, UK or Enzygnost,
Behring, Marburg, Germany) and particle agglutination
test assay (Serodia, Fujirebio Inc, Tokyo, Japan). Samples
giving discrepant results were repeated in duplicates using
the same two tests. From 2007, HIV testing was done
using Determine (Abbot Japan Co, Tokyo, Japan). Posi-
tives were confirmed using Uni-Gold (Trinity Biotech plc,
Bray, Ireland). For any discrepant results Bioline (Standard
Diagnostics, Giheung-gu, Korea) was used. Patients who
were known to be HIV positive at the time of TB diagno-
sis were asked about ART use. Free ART was available in
the District from 2005. As well as patients’ self-reports, in-
formation on ART use was collected from patient-held
“health passports” which record details of treatments. Fur-
ther data on ART usage was also available from linked
studies in local ART clinics, which involve identifying pa-
tients on ART, if they give consent.
Statistical analysis was performed using STATA 11©
software (StataCorp, TX, USA). Patients were grouped
as ‘not on ART’, ‘on ART ≤6 months’, ‘on ART >6 months’
or ‘HIV negative’. Duration on ART was included to dif-
ferentiate the effect of prolonged improved immune func-
tion from the early period in which TB could result from
unmasking or continued poor immunity [21]. The main
analysis was restricted to pulmonary TB cases with known
HIV status. The effects of HIV and ART status were evalu-
ated using multivariable logistic regression with sputum
smear positivity (among 766 study participants) and cavi-
tation (among a subset of 310 study participants) as the
outcome variables.
The data were derived from studies approved by the
Malawi National Health Sciences Research Committee
which is the local ethics committee and the Ethics
Committee of the London School of Hygiene & Tropical
Medicine.
Results
Characteristics of the study population
There were 1642 cases of TB aged ≥15 years registered
in the 7 year period from January 2005 to December
2011. Of the 1642 TB cases, 1024 (62%) were pulmonary
with laboratory confirmation, and of these, 766 (75%)
had known HIV status and were included in the analysis
(Figure 1). This included 689 (90%) who were culture-
positive.
Those with unknown HIV status were older than pa-
tients with known HIV status but there was no evidence
for other differences in terms of gender or socio-
economic status. There were differences in age, sex and
socio-economic characteristics between HIV negative
and HIV positive patients. HIV negative patients were
older, more commonly male, more likely to be farmers
and to have received less education. Previous TB was
more common in HIV positive patients, particularly
those who had been on ART for more than 6 months.
Table 1 shows the prevalence of smear positivity and
lung cavitation by patient characteristics among pulmon-
ary TB cases. Of the 766 cases, 368 (48%) were female.
The prevalence of HIV infection was high, with 475
(62%) of the 766 TB cases being HIV positive. Of the
475 patients with HIV infection 191 (40%) had initiated
ART by the time they were diagnosed with TB.
Chest radiographs were available for 310 (40%) of the
766 patients. A higher proportion of HIV negative pa-
tients had chest radiographs, and these were slightly
more common in men, but there was no evidence that
having a chest radiograph was associated with age, or
socio-economic status of the study participant.
Smear positivity and cavitation
Overall, 691 (90%) of the 766 patients had at least one
sputum smear positive for acid-fast bacilli, and 158
(51%) of the 310 patients with X-rays had evidence of
cavitation (Table 1). The proportion smear positive was
higher in HIV negative patients (95%) than in HIV posi-
tive patients (88%). Among those who were HIV posi-
tive, the proportion smear positive was highest for those
on ART for less than 6 months (93%) and lowest in
those not on ART (85%). Cavitation was more common
in the HIV negative (59%) than in those who were HIV
positive (44%). It was present in 54% of those on ART
for >6 months and 40% of those not on ART.
Table 2 shows the association between HIV and ART
status with sputum smear positivity and cavitation. After
adjusting for age and sex the association between HIV sta-
tus and smear positive pulmonary TB remained. HIV
negativity was associated with nearly three times increase
in the odds of smear positivity compared to HIV positive
patients (adjusted OR = 2.91, 95% CI 1.53 – 5.55). HIV
positive patients on ART ≤6 months had more than twice
the odds of being smear positive compared to the HIV
positive not on ART (adjusted OR = 2.33, 95% CI 1.01 –
5.39) while those on ART >6 months had nearly one and
half times the odds of smear positivity (adjusted OR =
1.43, 95% CI 0.68 – 2.99).
After adjusting for age and sex, HIV negativity was as-
sociated with nearly twice the odds of cavitation of those
who were HIV positive (adjusted OR = 1.97, 95% CI
1.20 – 3.23). HIV positive individuals who were on
ART > 6 months had more than one and half times in-
crease in the odds of cavitation as compared to HIV
positive patients not on ART (adjusted OR = 1.68, CI
0.78 – 3.63). Adjustment for other possible confounders
(history of TB, level of education and occupation) made
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little difference to the results for smear positivity or
cavitation.
Discussion
This study shows that smear positivity and radiological
changes in laboratory confirmed TB patients diagnosed
in a rural northern Malawian population were affected
by the individual’s HIV and ART status. HIV-infected in-
dividuals were significantly less likely to have positive
sputum smears and lung cavitation than those who were
HIV negative, as found elsewhere [6,22]. ART appears to
increase smear positivity and cavitation in HIV positive
individuals although the proportions remained lower
than in HIV negative individuals.
Many studies have looked at ART and its effect on sur-
vival in HIV-infected individuals [23,24]. Fewer studies
have described the role of ART in the evaluation of
people suspected of having TB [25]. Tiffany et al. found
that among HIV positive TB patients in the US those
who were diagnosed in the late ART era were more
likely to have a positive smear compared to those diag-
nosed in the early ART era [26]. A study in Italy found
that cavitation was more common in HIV infected TB
patients who were on ART compared to those not on
ART [27]. Sharma et al. in India showed that HIV positive
individuals with a moderate functional immune system di-
agnosed with pulmonary TB had sputum smears that were
more likely to be positive for acid fast bacilli than those
with higher levels of immunosuppression [28].
The positive association between ART and smear posi-
tivity and cavitation suggests that ART may play a role
in shifting the disease pattern towards a more typical
appearance, similar to that found in HIV negative indi-
viduals due to restoration of immune function. An in-
creasing proportion of HIV–infected TB patients are
likely to present with a laboratory confirmed TB diagno-
sis or a typical radiographic appearance on a chest radio-
graph. The introduction of ART among HIV–infected
individuals co-infected with TB could be one of the most
important factors in modifying the clinical presentation
of TB disease in HIV infected individuals. Advanced
HIV disease is known to be associated with lower rates
of sputum smear positivity and therefore less infectivity
[29]. In this new era in which many countries have
scaled up ART delivery, ART could result in increased
infectiousness of an individual as improved immune
Figure 1 Flowchart showing pulmonary TB patients included in the analysis.
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status shifts towards sputum smear positivity. With the
move towards integrated HIV/TB care, the potential for
transmission of M. tuberculosis in clinic settings is in-
creased. WHO has recommended implementation of TB
infection control measures, especially in healthcare facil-
ities providing HIV care. These measures include a TB in-
fection control plan comprised of managerial (e.g. use of
building space, on-going TB surveillance of healthcare
workers); administrative (e.g. triage to identify people with
TB symptoms, separation of infectious cases, reduction of
waiting times); environmental (e.g. maximising ventilation
systems) and personal protection measures (e.g. use of
N95 particulate respirators by healthcare workers) to re-
duce nosocomial TB transmission. Individuals living with
HIV should be provided with ART and isoniazid prevent-
ive therapy if eligible [30].
In the study 25% of eligible study participants had un-
known HIV status. This should not affect the comparisons
of HIV positive and negative individuals, and since those
with unknown status had similar socio-demographic char-
acteristics as those with known status it should not affect
generalisability of the results. The high proportion smear
positive in this study may be partly attributed to restric-
tion of the study to those who were smear or culture posi-
tive, and to examining smears in a research environment
using fluorescence microscopy, which may not be readily
available under routine health services and which has been
shown to be more sensitive than ZN microscopy [19].
CD4 cell counts were not routinely available so we were
unable to explore how the immune status affected the
smear status. Although some patients self-reported their
ART status, the availability of data from health passports
and ART registered patients in the district is likely to have
minimised misclassification.
Only 310/766 (40%) of the pulmonary TB cases had
chest radiographs. Some of the patients probably had
missing radiographs because they had died before a
radiograph could be taken. Since chest radiographs were
mainly done in individuals eligible for immunological
studies, which excluded pregnant women and individuals
taking steroids or suffering from diabetes or cancer, this
could have affected generalisability of the results, but
only 14 (1.8%) of the laboratory-confirmed pulmonary
TB patients with known HIV status were excluded from
immunological studies based on these criteria. Although
there were some differences in gender and HIV prevalence
between those who had a radiograph and those who did
not, there was little difference by age, socio-economic sta-
tus or clinical presentation.
The sample size for this analysis was small so there was
limited power to investigate effects by duration of ART.
Some patients might have had active subclinical disease at
the time of ART initiation and presentation of symptom-
atic disease might have arisen from ART-induced restor-
ation of an immune reaction against M. tuberculosis
(unmasking) [21]. There is a suggestion that cavitation
was more common later, which would be expected with
further improvement in immune function [27].
Conclusion
Wide scaling up of ART in developing countries and early
initiation of treatment is likely to change the clinical pres-
entation among TB patients with HIV co-infection to a
pattern more similar to that in HIV negative TB patients.
While this is more easily diagnosed, especially in settings
Table 1 Prevalence of sputum smear positivity and
cavitation by patient characteristics among pulmonary
TB patients
Smear positive Cavitation
Characteristic n/N (%) n/N (%)
Overall 691/766 (90%) 158/310 (51%)
HIV status
HIV positive 416/475 (88%) 72/164 (44%)
HIV negative 275/291 (95%) 86/146 (59%)
ART status
HIV positive not on ART 242/284 (85%) 34/84 (40%)
HIV positive on ART 0 – 6 months 93/100 (93%) 16/39 (41%)
HIV positive on ART >6 months 81/91 (89%) 22/41 (54%)
History of previous TB
No 606/668 (91%) 140/279 (50%)
Yes 82/91 (90%) 18/30 (60%)
Age (years)
15 – 29 175/185 (95%) 47/81 (58%)
30 – 44 331/368 (90%) 68/142 (48%)
45 – 59 133/152 (88%) 31/59 (53%)
≥60 52/61 (85%) 12/28 (43%)
Sex
Male 365/398 (92%) 92/175 (53%)
Female 326/368 (89%) 66/135 (49%)
Education
Never or lower primary 187/206 (91%) 41/78 (53%)
Higher primary 306/339 (90%) 76/134 (57%)
Secondary 107/113 (95%) 25/47 (53%)
Tertiary 76/91 (84%) 13/44 (30%)
Occupation
Farmer 349/387 (90%) 86/156 (55%)
Professional 60/67 (90%) 7/29 (24%)
Skilled manual 86/90 (96%) 20/41 (49%)
Unskilled 108/122 (89%) 26/46 (57%)
Small trader 68/78 (87%) 12/26 (46%)
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Table 2 Association of HIV and ART status with sputum smear positivity (amongst 766 participants) and cavitation (amongst 310 participants)
Outcomes Smear positivity (n = 766) Cavitation (n = 310)
Univariable analysis Adjusted for age and sex Univariable analysis Adjusted for age and sex
Characteristic Crude OR (95% CI) p-value Adj OR (95% CI) p-value(a) Crude OR (95% CI) p-value Adj OR (95% CI) p-value(a)
HIV status
HIV positive 1.00 1.00 1.00 1.00
HIV negative 2.44 (1.37 – 4.32) 0.002 2.91 (1.53 – 5.55) <0.001 1.83 (1.17 – 2.88) 0.009 1.97 (1.20 – 3.23) 0.007
ART status
HIV positive not on ART 1.00 1.00 1.00 1.00
HIV positive on ART 0 – 6 months 2.31 (1.00 – 5.31) 0.095 2.33 (1.01 – 5.39) 0.091 1.02 (0.47 – 2.22) 0.349 0.92 (0.41 – 2.03) 0.328
HIV positive on ART >6 months 1.41 (0.67 – 2.93) 1.43 (0.68 – 2.99) 1.70 (0.80 – 3.61) 1.68 (0.78 – 3.63)
OR = Odds Ratio; Adj OR = Adjusted Odds Ratio; CI = Confidence Interval.
(a)Likelihood ratio test p-value.
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relying on sputum microscopy, it is also more infectious
than the disease in HIV co-infected TB patients who are
ART-naive. Infection control measures in ART clinics are
important to limit the spread of TB.
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